Press Resease

Parkinson’s Disease Therapeutics Market by Drug Class (Levodopa Combination, Dopamine Agonists, Monoamine Oxidase B (MAO-B) Inhibitors, Anticholinergic Drugs, Catechol-O-Methyltransferase (COMT) Inhibitors, and Others), by Route of Administration (Oral, Transdermal, Subcutaneous, and Intestinal Infusion), and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Sales): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 31-May-2019 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-2858 Status : Published

Global Parkinson’s disease therapeutics market expected to generate around USD 5.28 billion by 2025, at a CAGR of around 10.6% between 2019 and 2025. Parkinson’s disease (PD) is a nervous system disorder that increases in severity with time. The disease is characterized by its bradykinesia, rigidity, tremor, and postural instability.

Description

The report covers a forecast and an analysis of the Parkinson’s disease therapeutics market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes drivers and restraints of the Parkinson’s disease therapeutics market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Parkinson’s disease therapeutics market on a global level.

In order to give the users of this report a comprehensive view of the Parkinson’s disease therapeutics market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Parkinson’s Disease Therapeutics Market

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis. Moreover, the study covers price trend analysis and product portfolio of various companies according to regions.

The study provides a decisive view of the Parkinson’s disease therapeutics market by segmenting it based on drug class, route of administration, distribution channel, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further classification into major countries.

Some players of the global Parkinson’s disease therapeutics market are Teva Pharmaceutical Industries, STADA Arzneimittel, Impax Laboratories, Novartis, F. Hoffmann-La Roche, Merck & Co., UCB Inc., GlaxoSmithKline, AbbVie, and Valeant Pharmaceuticals International.

This report segments the global Parkinson’s disease therapeutics market into:

Global Parkinson’s Disease Therapeutics Market: Drug Class Analysis

  • Levodopa Combination
  • Dopamine Agonists
  • Monoamine Oxidase B (Mao-B) Inhibitors
  • Anticholinergic Drugs
  • Catechol-O-Methyltransferase (COMT) Inhibitors
  • Others

Global Parkinson’s Disease Therapeutics Market: Route of Administration Analysis

  • Oral
  • Transdermal
  • Subcutaneous
  • Intestinal Infusion

Global Parkinson’s Disease Therapeutics Market: Distribution Channel Analysis

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales

Global Parkinson’s Disease Therapeutics Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Parkinson's disease therapeutics market, 2016-2025 (USD Billion)
    • 2.2. Global Parkinson's disease therapeutics market: Snapshot
  •  
  • Chapter 3. Parkinson's Disease Therapeutics Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global Parkinson's disease therapeutics market drivers: impact analysis
      • 3.2.2. Increasing environmental factors and genetic heredity causing Parkinson's
    • 3.3. Market Restraints
      • 3.3.1. Global Parkinson's disease therapeutics market restraints: impact analysis
      • 3.3.2. Patent expiration of key branded drugs and side-effects of therapeutic drugs
    • 3.4. Opportunities
      • 3.4.1. Promising products in the pipeline
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by drug class
      • 3.6.2. Market attractiveness analysis, by route of administration
      • 3.6.3. Market attractiveness analysis, by distribution channel
      • 3.6.4. Market attractiveness analysis, by region
  •  
  • Chapter 4. Global Parkinson's Disease Therapeutics Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Parkinson's disease therapeutics market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4. Research and development and regional expansion
    • 4.3. Price trend analysis
  •  
  • Chapter 5. Global Parkinson's Disease Therapeutics Market - Drug Class Analysis
    • 5.1. Global Parkinson's disease therapeutics market: drug class overview
      • 5.1.1. Global Parkinson's disease therapeutics market revenue share, by drug class, 2018 and 2025
    • 5.2. Levodopa Combination
      • 5.2.1. Global Parkinson's disease therapeutics market for levodopa combination, 2016-2025 (USD Billion)
    • 5.3. Dopamine Agonists
      • 5.3.1. Global Parkinson's disease therapeutics market for dopamine agonists, 2016-2025 (USD Billion)
    • 5.4. Monoamine Oxidase B (MAO-B) Inhibitors
      • 5.4.1. Global Parkinson's disease therapeutics market for monoamine oxidase B (MAO-B) Inhibitors, 2016-2025 (USD Billion)
    • 5.5. Anticholinergic Drugs
      • 5.5.1. Global Parkinson's disease therapeutics market for anticholinergic drugs, 2016-2025 (USD Billion)
    • 5.6. Catechol-O-Methyltransferase (COMT) Inhibitors
      • 5.6.1. Global Parkinson's disease therapeutics market for catechol-o-methyltransferase (COMT) inhibitors, 2016-2025 (USD Billion)
    • 5.7. Others
      • 5.7.1. Global Parkinson's disease therapeutics market for others, 2016-2025 (USD Billion)
  •  
  • Chapter 6. Global Parkinson's Disease Therapeutics Market - Route of Administration Analysis
    • 6.1. Global Parkinson's disease therapeutics market: route of administration overview
      • 6.1.1. Global Parkinson's disease therapeutics market revenue share, by route of administration, 2018 and 2025
    • 6.2. Oral
      • 6.2.1. Global Parkinson's disease therapeutics market for oral, 2016-2025 (USD Billion)
    • 6.3. Transdermal
      • 6.3.1. Global Parkinson's disease therapeutics market for independent transdermal, 2016-2025 (USD Billion)
    • 6.4. Subcutaneous
      • 6.4.1. Global Parkinson's disease therapeutics market for subcutaneous, 2016-2025 (USD Billion)
    • 6.5. Intestinal Infusion
      • 6.5.1. Global Parkinson's disease therapeutics market for intestinal infusion, 2016-2025 (USD Billion)
  •  
  • Chapter 7. Global Parkinson's Disease Therapeutics Market - Distribution Channel Analysis
    • 7.1. Global Parkinson's disease therapeutics market: distribution channel overview
      • 7.1.1. Global Parkinson's disease therapeutics market revenue share, by distribution channel, 2018 and 2025
    • 7.2. Hospital Pharmacy
      • 7.2.1. Global Parkinson's disease therapeutics market for hospital pharmacy, 2016-2025 (USD Billion)
    • 7.3. Retail Pharmacy
      • 7.3.1. Global Parkinson's disease therapeutics market for retail pharmacy, 2016-2025 (USD Billion)
    • 7.4. Online Sales
      • 7.4.1. Global Parkinson's disease therapeutics market for online sales, 2016-2025 (USD Billion)
  • Chapter 8. Global Parkinson's Disease Therapeutics Market - Regional Analysis
    • 8.1. Global Parkinson's disease therapeutics market: regional overview
      • 8.1.1. Global Parkinson's disease therapeutics market revenue share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.2.2. North America Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
      • 8.2.3. North America Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.2.4. The U.S.
        • 8.2.4.1. The U.S. Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.2.4.2. The U.S. Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.2.4.3. The U.S. Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.2.5. Canada
        • 8.2.5.1. Canada Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.2.5.2. Canada Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.2.5.3. Canada Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 8.3. Europe
      • 8.3.1. Europe Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.3.2. Europe Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
      • 8.3.3. Europe Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.3.4. UK
        • 8.3.4.1. UK Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.3.4.2. UK Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.3.4.3. UK Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.3.5. Germany
        • 8.3.5.1. Germany Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.3.5.2. Germany Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.3.5.3. Germany Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.3.6. France
        • 8.3.6.1. France Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.3.6.2. France Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.3.6.3. France Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.3.7. Rest of Europe
        • 8.3.7.1. Rest of Europe Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.3.7.2. Rest of Europe Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.3.7.3. Rest of Europe Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.4.2. Asia Pacific Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
      • 8.4.3. Asia Pacific Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.4.4. China
        • 8.4.4.1. China Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.4.4.2. China Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.4.4.3. China Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.4.5.2. Japan Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.4.5.3. Japan Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.4.6. India
        • 8.4.6.1. India Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.4.6.2. India Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.4.6.3. India Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.4.7. Rest of Asia Pacific
        • 8.4.7.1. Rest of Asia Pacific Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.4.7.2. Rest of Asia Pacific Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.4.7.3. Rest of Asia Pacific Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 8.5. Latin America
      • 8.5.1. Latin America Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.5.2. Latin America Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
      • 8.5.3. Latin America Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.5.4.2. Brazil Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.5.4.3. Brazil Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.5.5.2. Rest of Latin America Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.5.5.3. Rest of Latin America Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.6.2. The Middle East and Africa Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
      • 8.6.3. The Middle East and Africa Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
  •  
  • Chapter 9. Company Profile
    • 9.1. Teva Pharmaceutical
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. STADA Arzneimittel
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. Impax Laboratories
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Novartis
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. F. Hoffmann-La Roche
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. Merck & Co.
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. UCB, Inc.
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. GlaxoSmithKline
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. AbbVie
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Valeant Pharmaceuticals International
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Product portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments

Methodology

Free Analysis

Parkinson’s disease (PD) is a nervous system disorder that increases in severity with time. The disease is characterized by its bradykinesia, rigidity, tremor, and postural instability. Some of the most common symptoms of Parkinson’s disease include arms, hand, or leg tremors, problems associated with balancing and walking, stiff muscles, and slow physical movements. Other symptoms include constipation, trouble in swallowing, dementia, fixed or blank expressions, and speech disabilities. However, the exact cause causing the disease is still not known, but it generally affects the patients of the older age group, i.e., mostly more than 50 years in age.

The global Parkinson’s disease therapeutics market is likely to be driven by the launch of prominent pipeline drugs like ND0612H, Accordion Pill, APL-130277, P2B-001, etc., increasing research and development activities for the development of novel Parkinson’s disease therapeutic drugs, and rising Parkinson’s disease incidences. The incidence rate of Parkinson’s disease increases with growing age. Additionally, the world’s population above 65 years is likely to increase from 6.8% in 2000 to almost 17% by 2050, which is a major driver for Parkinson’s disease therapeutics market growth.

Global Parkinson’s Disease Therapeutics Market

Based on drug class, the market includes dopamine agonists, catechol-o-methyltransferase (COMT) inhibitors, anticholinergic drugs, levodopa combination, monoamine oxidase B (MAO-B) inhibitors, and others. Based on route of administration, the market includes transdermal, oral, subcutaneous, and intestinal infusion. The oral segment held a significant share of the market in 2018 globally. The distribution channel of the Parkinson’s disease therapeutics market is fragmented into retail pharmacy, online sales, and hospital pharmacy. The retail pharmacy segment dominated the global market in 2018 and is projected to hold a significant market share in the future.

By region, Europe holds a major share of the global Parkinson’s disease therapeutics market followed by the North American region. Favorable medical reimbursement policies, rising funding and grants for research, high Parkinson’s disease prevalence, and growing awareness about the disease are contributing to the European Parkinson’s disease therapeutics market. In the North America market, alone there are more than 10 different drugs under phase III clinical pipeline studies for treating different symptoms of Parkinson’s disease in the U.S. alone. The Asia Pacific Parkinson’s disease therapeutics market is likely to show a moderate CAGR, owing to a large base of the elderly population suffering from Parkinson’s disease, particularly in China and Japan.

Some players of the global Parkinson’s disease therapeutics market are Teva Pharmaceutical, STADA Arzneimittel, Impax Laboratories, Novartis, F. Hoffmann-La Roche, Merck & Co., UCB Inc., GlaxoSmithKline, AbbVie, and Valeant Pharmaceuticals International.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com